Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'gambogic acid 20172'

Search results for: 'gambogic acid 20172'

Items 31-40 of 44

Page
per page
  1. MG-262
    A8179 MG-262
     1 Citation
    Target: Proteasome
    Summary: Proteasome inhibitor
      ≥24.57 mg/mL
  2. TUG-770
    A3895 TUG-770
    Target: Free Fatty Acid Receptors
    Summary: FFA1/GPR40 agonist
      insoluble in H2O; ≥11.85 mg/mL
  3. MLN8054
    A4114 MLN8054
    Target: Aurora Kinases
    Summary: Aurora A inhibitor
      insoluble in EtOH; insoluble in H2O; ≥39.05 mg/mL
  4. AGN 194310
    B4702 AGN 194310
     1 Citation
    Target: RARs
    Summary: pan-RAR antagonist
      insoluble in H2O; ≥16.8 mg/mL
  5. Exendin-4
    A3408 Exendin-4
    Target: Glucagon-like peptide 1 (GLP-1) receptors
    Summary: GLP-1 activator
      ≥145 mg/mL
  6. BLZ945
    B4899 BLZ945
     1 Citation
    Target: CSF-1R
    Summary: CSF-1R kinase inhibitor
      insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL
  7. Peptide YY(3-36), PYY, human
    A1115 Peptide YY(3-36), PYY, human
    Target: NPY Receptors
    Summary: Y2R agonist
      ≥405 mg/mL
  8. Panobinostat (LBH589)
    A8178 Panobinostat (LBH589)
     10 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC inhibitor
      insoluble in H2O; insoluble in EtOH; ≥17.47 mg/mL
  9. EPZ5676
    A4166 EPZ5676
     1 Citation
    Target: DOT1L
    Summary: DOT1L inhibitor,potent and SAM competitive
      ≥28.15 mg/mL
  10. Bardoxolone methyl
    A3221 Bardoxolone methyl
    Target: Nrf2
    Summary: IKK inhibitor, potent antioxidant inflammation modulator
      ≥25.3 mg/mL

Items 31-40 of 44

Page
per page
Shop By
Now Shopping by
  1. Specificity Selective Remove This Item
  2. Reported Experiments Animal Experiments Remove This Item
Clear All
Shopping Options
Category
  1. Signaling Pathways 39item
  2. Natural Products 3item
Reversibility
  1. Reversible 5item
  2. Irreversible 1 item
Target
  1. Proteasome 1 item
  2. Histone Deacetylases (HDACs) 4item
  3. Aurora Kinases 1 item
  4. CSF-1R 1 item
  5. Farnesoid X receptors (FXRs) 1 item
  6. LPA Receptors 2item
  7. DOT1L 1 item
  8. Nrf2 1 item
  9. Glucagon-like peptide 1 (GLP-1) receptors 1 item
  10. Neuraminidases (NA) 1 item
  11. RARs 4item
  12. FAK 3item
  13. CREBBP 1 item
  14. EP300 1 item
  15. Pyk2 3item
  16. Calcium ionophores 1 item
  17. Insulin and Insulin-like Receptors 1 item
  18. AdipoR2 1 item
  19. Fatty-acid-binding proteins (FABPs) 1 item
  20. Free Fatty Acid Receptors 2item
  21. Farnesyl Diphosphate Synthases 1 item
  22. Calcium-activated chloride channels (CaCC) 1 item
  23. GPR35 1 item
  24. NPY Receptors 1 item
  25. RAR/RXR 1 item
  26. Opioid receptors 1 item
  27. Histamine H2 Receptors 1 item
  28. TRP Channel 1 item
  29. Xanthine oxidoreductases 1 item
  30. fibrinolysis 1 item
  31. GPR40 1 item
  32. PPAR 1 item
  33. HCV polymerase 1 item
  34. FAAH 1 item
Related Disease
  1. Acute Myelogenous Leukemia 1 item
  2. Acute Myeloid Leukemia 1 item
  3. Bladder Cancer 1 item
  4. Brain Injuries Studies 1 item
  5. Breast Cancer 7item
  6. Cancer 22item
  7. Colon Cancer 2item
  8. Colorectal Cancer 3item
  9. Epilepsy 1 item
  10. Glioblastoma 1 item
  11. Glioma 2item
  12. Hepatitis C 1 item
  13. Hepatocellular Carcinoma 3item
  14. HIV Infections 2item
  15. Inflammation 1 item
  16. Inflammatory Diseases 1 item
  17. Influenza 1 item
  18. Lymphoma 1 item
  19. Melanoma 1 item
  20. Mixed Lineage Leukemia 1 item
  21. Multiple Myeloma 1 item
  22. Myeloma 1 item
  23. Non-small Cell Lung Cancer 1 item
  24. Ovarian Cancer 1 item
  25. Pain Relief 1 item
  26. Pancreatic Cancer 7item
  27. Prostate Cancer 4item
  28. Renal Cancer 1 item
  29. Renal Cell Carcinoma 2item
  30. Type 2 Diabetes 5item